Trial Profile
Effectiveness of Vedolizumab Therapy in Inducing Clinical Remission in CD Patients Naïve to Anti-TNF and Its Capability to Halt Disease Progression
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Vedolizumab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- 07 May 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 13 Jul 2016 New trial record